National Hispanic Science Network on Drug Abuse

Mission Statement

The mission of the National Hispanic Science Network on Drug Abuse (NHSN) is to foster biomedical and behavioral research on drug use among Hispanics and to facilitate its application to practice and public health.

The NHSN is committed to increasing the rate of scientific discovery and its potential for reducing health disparities between Hispanics and other populations.

The NHSN is committed to increasing the involvement of Hispanic scientists in federally supported drug abuse research through mentoring, training, networking, and technical assistance.
National Steering Committee

José Szapocznik, Ph.D., Chair
Department of Psychiatry & Behavioral Sciences
University of Miami

Hortensia Amaro, Ph.D.
Northeastern University
Bouvé College of Health Sciences

Alexander Kopelowicz, M.D.
Department of Psychiatry
University of California, Los Angeles

Joe Martínez, Ph.D.
Department of Biology
University of Texas at San Antonio

J. Bryan Page, Ph.D.
Department of Anthropology
University of Miami

Rafaela Robles, Ed.D.
Department of Community Health
Universidad Central del Caribe

Daniel Santisteban, Ph.D.
Department of Psychiatry & Behavioral Sciences
University of Miami

Avelardo Valdez, Ph.D.
Graduate School of Social Work
University of Houston

Nora Volkow, M.D.
Life Sciences Directorate
Brookhaven National Laboratory
DAY ONE: Thursday, September 26, 2002
Scientific Conference Program

8:30 am - 6:30 pm  
**Registration**  
Sierra Suite Lobby Area, 2nd Floor

ALL PRESENTATIONS IN HIRO ROOM UNLESS OTHERWISE NOTED

2:00 pm - 2:30 pm  
**Welcoming & Introductory Remarks**  
Dr. Richard Millestein, National Institute on Drug Abuse  
Dr. José Szapocznik, Chair  
NHSN National Steering Committee  
Ms. Ana Anders, National Institute on Drug Abuse

2:30 pm - 3:15 pm  
**Imaging the Addicted Brain**  
Dr. Nora Volkow  
Brookhaven National Laboratory

3:15 pm - 4:00 pm  
**Medications Development for Opiate & Stimulant-Dependent Disorder**  
Dr. Frank Vocci  
National Institute on Drug Abuse

4:00 pm - 4:15 pm  
**BREAK**
4:15 pm - 5:30 pm  
**Interdisciplinary Perspectives on Hispanic Drug Abuse Research: A Case Study of Craving and Relapse**

*Chair:* Dr. Edward Castañeda  
University of Arizona

*Presenters:*  
Dr. Antonio Cepeda-Benito  
Texas A & M University  
Dr. José Szapocznik  
University of Miami

*Discussants:*  
Dr. Frank Vocci,  
National Institute on Drug Abuse  
Dr. Nora Volkow  
Brookhaven National Laboratory

5:30 pm - 6:30 pm  
**BREAK**

6:30 pm - 7:30 pm  
**Reception (Sierra Lobby)**

Hugo Fernandes, Guitarist

7:30 pm - 9:00 pm  
**Dinner and Awards Ceremony (Ballroom A)**

*Guest Speaker:* Vice Admiral Richard Carmona  
Surgeon General of the United States

9:00 pm - Midnight  
**Social Event (Ballroom A)**

Antonio Madrigal (DJ), Hot Peppers Entertainment
DAY TWO: Friday, September 27, 2002
Scientific Conference Program

8:00 am - 8:45 am  Breakfast & Registration
Sierra Lobby First Floor

ALL PRESENTATIONS IN BALLROOM A FIRST FLOOR
UNLESS OTHERWISE SPECIFIED

8:45 am - 9:00 am  Introductory Remarks
Dr. Donald R. Vereen
National Institute on Drug Abuse

9:00 am - 10:00 am  Keynote Address
Dr. Glen Hanson
National Institute on Drug Abuse

10:00 am - 10:15 am  BREAK

10:15 am - 12:15 pm  Issues in Career Development for Hispanic Scientists
Chair: Dr. Ana Mari Cauce
University of Washington

Presenters:
Dr. Ron Durán
University of Miami
Dr. Steve López
University of California
Dr. Patricia Molina
University of Louisiana
Dr. William Vega
Robert Wood Johnson Medical School
DAY TWO: Friday, September 27, 2002
Scientific Conference Program

12:15 pm - 1:45 pm Luncheon Address

Dr. Andrea Barthwell
White House Office of National Drug Control Policy

1:45 pm - 2:45 pm Public Health Research of Co-occurring Psychiatric and Drug Use Disorders

Dr. Wilson Compton
National Institute on Drug Abuse

2:45 pm - 3:00 pm BREAK

3:00 pm - 4:00 pm International Opportunities in Drug Abuse Research

Presenters: Dr. Guido Belsasso
Comisionado del Consejo Nacional Contra las Adicciones, Mexico
Don Gonzalo Robles- Orozco (Invited)
Delegado del Gobierno para el Plan Nacional Sobre las Drogas, España

4:00 pm - 5:00 pm Blending Research and Practice Symposium

Chair: Dr. Daniel Santisteban
University of Miami

Presenters: Dr. Rafaela Robles
Universidad Central del Caribe
Dr. Felipe Castro
Arizona State University

5:00 pm Adjourn Scientific Program
DAY THREE: Saturday, September 28, 2002
Scientific Conference Program

8:00 am - 9:00 am  Breakfast
Sierra Lobby

ALL PRESENTATIONS IN BALLROOM A

9:00 am - 10:30 am  Grant Proposal Writing Workshop

Chair:          Dr. Ivan Montoya
                National Institute on Drug Abuse

Co-Chair:      Dr. Wilson Compton
                National Institute on Drug Abuse

Presenters:
   Dr. Sergio Aguilar-Gaxiola,
       California State University-Fresno
   Dr. Carlos Blanco
       New York State Psychiatric Institute
   Dr. Edward Castañeda
       Arizona State University
   Dr. Joe Frascella
       National Institute on Drug Abuse
   Dr. Isaac Montoya
       Affiliated Systems Corporation
   Dr. Moira O’Brien
       National Institute on Drug Abuse
   Dr. Angela Pattatucci
       University of Puerto Rico

10:30 am - 10:45 am  BREAK

10:45 am - 12:00 Noon  Grant Proposal Writing Workshop (Continued)
DAY TWO: Friday, September 27, 2002
Scientific Conference Program

INTERNATIONAL DINNER WILL BE HELD IN HIRO ROOM FIRST FLOOR

7:00 pm - 9:00 pm

International Dinner (Advance registration required)

Chair: Dr. Antonio Cepeda-Benito
Texas A & M University

Co-Chair: Dr. Steve Gust
National Institute on Drug Abuse

Guest Speaker:
Don Gonzalo Robles-Orozco (Invited)
Delegado del Gobierno para el Plan Nacional Sobre las Drogas
España

Scientist Delegates from Spain:

Dr. D. Fernando Martín-Pinillos Marco
Coordinador del Instituto Nacional de Investigación y Formación en Drogodependencias

Dr. Javier Hernández González
Vocal Asesor de Comunicación en el Gabinete del Delegado del Gobierno para el Plan Nacional sobre Drogas

Dr. Miguel Navarro García
Profesor Titular y Director Departamento de Psicobiología Facultad de Psicología Universidad Complutense de Madrid
1:00 pm  
*Adjourn National Conference*

12:00 noon - 1:00 pm  
*Working Lunch*

1:00 pm - 5:00 pm  
*National Network Meeting: National Strategic Plan*
   Chair: Dr. Hortensia Amaro  
   Northeastern University

3:00 pm - 3:15 pm  
*BREAK*

3:15 pm - 5:00 pm  
*National Network Meeting: National Strategic Plan (Continued)*

5:00 pm  
*Adjourn National Network Meeting*
Imaging the Addicted Brain
Nora Volkow, M.D., Brookhaven National Laboratory

The involvement of dopamine (DA) in drug reinforcement is well established but much less in known about its contribution to addiction. We have used Positron Emission Tomography to investigate in humans the role that DA has on drug reinforcement, addiction and drug vulnerability. We have shown that during drug intoxication increases in striatal DA are associated with the drug’s reinforcing effects only if the DA changes occur rapidly. These results corroborate the relevance of drug-induced DA increases and of pharmacokinetics in the rewarding effects of drugs in humans. During withdrawal we have shown significant reductions in DA D2 receptors and in DA release in drug abusers, which is likely to result in decreased sensitivity to non-drug related reinforcing stimuli. The DA D2 reductions were associated with decreased activity in orbitofrontal cortex, which we postulate is one of the mechanisms underlying compulsive drug administration in the addict. In fact during craving the orbitofrontal cortex become hyperactive in proportion to the desire for the drug. In non-drug abusing subjects striatal DA D2 receptors levels predicted the reinforcing responses to stimulant drugs providing evidence that striatal DA D2 receptors modulate reinforcing responses to stimulants in humans and may underlie predisposition for drug self-administration. Supported by DOE (OBER), NIDA, and ONDCP.

Medications Development for Opiate & Stimulant-Dependent Disorder
Frank Vocci, Ph.D., National Institute on Drug Abuse

Opiate dependence is a chronic, relapsing disorder with associated mortality and serious morbidity. The majority of the pharmacotherapy research in developing medications for stimulant addiction has focused on cocaine although recently NIDA has created a methamphetamine medications development program. Two approaches have been used in the development of medications for the treatment of cocaine dependence. The first approach, called "top-down," tests currently available medications as putative treatment medications in clinical trials. The second approach, "bottom up," seeks to
Medications Development for Opiate & Stimulant-Dependent Disorder (Cont.)

develop medications based on ability to modulate cocaine or its chronic effects on brain systems. Using this approach, dopamine transporter inhibitors have been advanced to clinical testing and selective dopamine receptor ligands are being advanced to clinical testing. In terms of future directions, the program is refocusing on discovery and testing of medications that modulate processes involved in the propensity to relapse: e.g., cueing, priming and stress-induced increases in cocaine intake. Inasmuch as these processes may be involved to some extent in all drug-addicted states, the program is evolving towards medications as relapse prevention agents for all drug dependencies.

Interdisciplinary Perspectives on Hispanic Drug Abuse Research:
A Case Study of Craving and Relapse
Panel Chair: Edward Castañeda, Ph.D., Arizona State University

The panel will explore how craving and relapse issues play out at different levels (e.g., biological, family) and across disciplines. The panel will help conference participants understand the multiplicity of issues in craving and relapse research by drawing from knowledge obtained in applied clinical settings as well as more basic settings. More specifically, how knowledge from one discipline can enhance the research in other disciplines will be exploited to determine how and when cross-disciplinary research can be valuable.

Issues in Career Development for Hispanic Scientists
Panel Chair: Ana Mari Cauce, Ph.D., University of Washington

The goal of this session is to discuss issues that we face in our career development both as Latino researchers and as behavioral and social scientists doing research within the substance abuse field. Participants will present a brief sketch of their career trajectory, and will then focus on one challenge that they have encountered and resolved to their satisfaction (e.g. negotiating a job offer, moving from one institution to another, getting tenure, etc.).

11
Public Health Research of Co-occurring Psychiatric and Drug Use Disorders
Wilson Compton, Ph.D., National Institute on Drug Abuse

It seems a quite straightforward notion that the public health perspective can be an appropriate model for drug abuse research, but the implications of this approach are far-reaching. Using co-occurring psychiatric illness to illustrate the public health research approach in practice, we have demonstrated that psychiatric disorders are very common among drug abusers. Despite the high prevalence, co-occurring psychiatric conditions often go unrecognized and/or untreated by substance abuse programs. Taking depression as a common and potentially treatable condition, the presentation will describe studies of the early identification and treatment of patients with comorbid depression. The goal is to show how applying public health research methods in practice will allow our work to have the maximum public health impact.

Blending Research and Practice Symposium
Symposium Chair: Daniel Santisteban, Ph.D., University of Miami

The goal of this panel is to highlight activities focused on blending research and practice that offer opportunities for Hispanic drug abuse treatment researchers. We hope to stimulate discussion as to the types of research that are needed in this important field. The first brief presentation focuses on a network of Addiction Technology Transfer Centers that is spreading across the country and that now has an important Hispanic Initiative. We will explore ways in which Hispanic researchers can introduce research into these initiatives. The second presentation reviews issues and approaches involved in conducting a cultural adaptation of a model for drug abuse treatment developed in the United States, for use with drug abuse clients in Mexico City, Mexico. The Matrix Model is an empirically-validated model for treating clients who are dependent on cocaine, and/or methamphetamine. The critical treatment adaptation question is, "What changes or clinical considerations are necessary to culturally adapt the Matrix treatment for effective use within Mexico?" A conceptual model is presented which guides the initial adaptation plan for its use with Mexican clients who are addicted to the use of stimulants. Discussion will revolve around the types of research needed to test the impact of these adaptations.
International Dinner
Chair: Antonio Cepeda-Benito, Ph.D., Texas A&M University

The Spanish government and their Delegación del Gobierno para el Plan Nacional sobre Drogas are hosting this first International Dinner. This event was created to increase opportunities for NHSN members to interact and collaborate with international scientists conducting Hispanic drug abuse research. Delegates from Spain will provide information about scientific opportunities and research in Spain, identifying areas in which NHSN and Spanish scientists can join forces to address drug problems in both the U.S. and Spain. The International Dinner will also include the participation of Dr. Steve Gust, Acting Director of the International Research Program of NIDA. Dr. Gust will describe how NIDA funds international research and training, and describe NIDA’s new international initiatives.

Grant Proposal Writing Workshop
Chair: Ivan Montoya, M.D., M.P.H., National Institute on Drug Abuse

The purpose of this workshop is to bring together Hispanic scientists, NIDA funded scientists, and NIDA Program Officials with common research areas of interest to work in small groups in advancing a draft of a grant proposal to be submitted to NIDA for funding. Workshop participants are expected to bring a grant proposal on drug abuse research to be discussed during the workshop. There will be an introductory presentation of 15 minutes to inform participants about the workshop procedures. Then, participants will break up into small groups for discussion of their grant proposals. At the end of the workshop participants will be asked to complete a workshop evaluation form.

National Network Meeting: National Strategic Plan
Chair: Hortensia Amaro, Ph.D., Northeastern University

Members of the NHSN Expert Panel on the Development of a National Strategic Plan on Hispanic Drug Abuse Research will present the workplan for development of the plan. Members of the NHSN will be engaged in a discussion on the workplan in order to provide input on its content and development process. The plan will be completed in the summer of 2003 and presented to the NIDA director, RWJF staff and other funders of substance abuse research.
Sergio Aguilar-Gaxiola, M.D.

Sergio Aguilar-Gaxiola is a Professor at California State University, Fresno. He trained both as a Medical Doctor at the Autonomous University of Guadalajara in Mexico (1977) and obtained a Doctoral Degree (Ph.D.) in Clinical-Community Psychology at Vanderbilt University (1986). He did postdoctoral studies in clinical and health services research at the University of California, San Francisco. He is the on-site Principal Investigator of the Mexican American Prevalence and Services Survey (MAPSS), the largest mental health study conducted in the U.S. on Mexican Americans. He is also the Coordinator for Latin America and the Caribbean of the World Health Organization’s (WHO) World Mental Health (WMH) initiative. He is a member of the Editorial Board for the World Health Organization’s (WHO) Composite International Diagnostic Interview (CIDI) and a member of the World Health Organization’s International Consortium in Psychiatric Epidemiology (ICPE). He is also a Quality Assurance Advisor of WHO’s World Health Surveys. Dr. Aguilar-Gaxiola is the author of several scientific publications and has received several awards for his mental health work such as the Peabody College of Vanderbilt University Distinguished Alumnus Award (1998), the Medal of Congress (“Medalla de la Cámara de Diputados”) of Chile for work related to mental health research (1999), and the 2002 Outstanding Latino Faculty in Higher Education Award by the American Association for Higher Education, Hispanic Caucus (2002). He serves on the Executive Committee of the Board of Directors of the National Mental Health Association (NMHA) and is the Vice-Chair of the NMHA’s Prevention and Children’s Mental Health Services Committee. He is also a member of the Board of Trustees of the American Society of Hispanic Psychiatry. His research deals with minority mental health (e.g., prevalence of mental disorders, risk and protective factors, mental health service utilization patterns, access to care, and treatment outcomes), cross-national comparative epidemiologic research on patterns and correlates of mental disorders in general population samples. He has been very active lately translating mental health research into practical information to be utilized by consumers (and their families), health professionals, service administrators, and policy makers with the purpose of informing mental health policy decisions and guiding program development at the local, national, and international level.

Hortensia Amaro, Ph.D.

Hortensia Amaro received her Ph.D. in Psychology from the University of California, Los Angeles in 1982. She is currently Distinguished Professor at the Bouvé College of Health Sciences in Northeastern University. She has published over 60 scientific publications on epidemiological and community-based studies of alcohol and drug use among adolescents and adults; on the effectiveness of HIV/AIDS prevention programs; and on substance abuse treatment of women. Her current research is focused on improving the connections between public health research and public health practice and the development of national model substance abuse treatment and prevention programs targeted to Latina and African American women and adolescents. This research has been supported by grants the National Institute on Drug Abuse, the Centers for Disease Control and Prevention, the Office of Substance Abuse Prevention, and Health Resources and Services Administration, among others. Her professional contributions have been recognized by numerous professional and government organizations. These awards include: an Honorary Doctoral Degree in Humane Letters from Simmons College; the American Psychological Association’s Early Career Award for Contributions to Psychology in the Public Interest; the APA Award for Women’s Health Research; the Association of Women in Psychology’s Publication Award; the Mass. Public Health Association’s Alfred Frechette Award for Contributions to Public Health; the Hispanic Mental Health Professional Association’s Rafael Tavares Award for Research, and the American Psychological Association Dalmas Taylor Award.
Presenters

Carlos Blanco, M.D., Ph.D.
Carlos Blanco received his M.D., Ph.D. in Medicine (M.D.)/Neuroscience (Ph.D.) from the Universidad Autónoma in Madrid in 1986. He is currently Assistant Professor of Psychiatry at Columbia University/New York State Psychiatric Institute. He has published over 25 journal articles and chapters in the areas of Pathological Gambling, Anxiety Disorders and Health Services Research. His current research is focused on Pathological Gambling with and without comorbid substance abuse. This research is supported by grants from NIDA, NARSAD, and the Alcohol Beverage Medical Research Foundation. Dr. Blanco has been recognized for his contributions and received the Van Ameringen Health Services Research Scholar Award from the American Psychiatric Association.

Edward Castañeda, Ph.D.
Edward Castañeda received his Ph.D. in Psychobiology from the University of Michigan in 1987. He is currently Associate Professor and Chair in the Department of Psychology at Arizona State University. He has published over 25 journal articles and chapters in the areas of physiological activity and the neurochemistry of compensatory and dysfunctional mechanisms following brain damage or neurodegeneration. His research is focused on the combination of molecular, biochemical and behavioral principles to develop gene therapies for the treatment of Parkinson’s disease. His research in the drug abuse arena has focused on the underlying bases for sensitization to repeated exposure to stimulant drugs, including these effects on conditional stimuli previously associated with drug exposure. This research is supported by a grant from Arizona State University. Dr. Castañeda has been recognized for his contributions and has received the Outstanding Instructor Award from Psi Chi National Honor, the Recognition Award for Meritorious Service and the Distinguished Faculty Award from the Arizona Association of Chicanos for Higher Education.

Felipe Gonzalez Castro, Ph.D.
Felipe González Castro received his Ph.D. in Clinical Psychology from the University of Washington in 1981. He is currently Professor of Clinical Psychology at Arizona State University. He has published over 50 journal articles and chapters in various health-related areas. His research is focused on motivational factors in drug abuse prevention, treatment, and relapse as well as incrementing cultural competence theory in program development and implementation, and in professional development. Dr. Castro has studied Hispanic health issues in the areas of health promotion and disease prevention in drug and tobacco use, cancer, diabetes mellitus, AIDS, and coronary heart disease. This research has been supported by grants from various agencies such as National Institute on Drug Abuse, the National Cancer Institute, COSSMHO, and the Arizona Department of Health Services, among others. Dr. Castro has been widely recognized for his contributions and has received the National Hispanic/Latino Community Prevention Network Outstanding Achievement Award for Research.
Ana Mari Cauce, Ph.D.
Ana Mari Cauce graduated from the University of Miami, earning degrees in English Literature and in Psychology in 1977, before going on to Yale University, where she earned her doctoral degree in Psychology, with a concentration in Child Clinical and Community Psychology. Dr. Cauce began teaching at the University of Washington in 1986. She currently holds The Earl R. Carlson Professorship in Psychology and has a joint appointment in the Department of American Ethnic Studies. She is also Director of the University Honors Program. Since she began her graduate work, Dr. Cauce has been particularly interested in normative and non-normative development in ethnic minority youth and in at-risk youth more generally. She has published more than 60 articles and chapters and has been recipient of grants from the W.T. Grant Foundation, the National Institute of Mental Health, the National Institute of Child Health and Human Development, and the National Institute of Alcoholism, and Alcohol Abuse. She is the recipient of numerous awards, including Recognition from the American Psychological Association for Excellence in Research on Minority Issues and the University of Washington's Distinguished Teaching Award.

Antonio Cepeda-Benito, Ph. D.
Antonio Cepeda-Benito received his Ph.D. from Purdue University in 1994. He is currently Associate Professor in the Department of Psychology at Texas A&M University. He has published over 25 journal articles and chapters in the areas of drug addiction and eating disorders. His current research is focused on the psychological processes involved in the formation, maintenance, and cessation of ingestive-compulsive behaviors and the study of learning factors that influence the development of drug tolerance. This research is being supported by grants from the National Institute on Drug Abuse and the Texas Department of Health. Dr. Cepeda-Benito has been recognized for his contributions and has received the Psychology Teacher of the Year and Academic Inspiration awards from Texas A&M University.

Wilson, Compton, Ph. D.
Wilson M. Compton, M.D., M.P.E. is Director of the Division of Epidemiology, Services and Prevention Research at the National Institute on Drug Abuse (NIDA) of the National Institutes of Health. Prior to joining NIDA, Dr. Compton was Associate Professor of Psychiatry at Washington University in Saint Louis and was Medical Director of Chemical Dependency Services at Barnes-Jewish Hospital. Dr. Compton received his undergraduate education from Amherst College. He attended medical school and completed his residency training in psychiatry at Washington University. He is a member of the Alpha Omega Alpha honor society as well as numerous professional organizations. He has been the principal or co-principal investigator of six federally funded grants and has published over 50 articles, 10 chapters, and several diagnostic interviews, including serving as "guest editor" of special issues of Drug and Alcohol Dependence and The International Review of Psychiatry.
Ron Durán, Ph.D.
Ron E. Franco Durán received his Ph.D. in Clinical Psychology from the University of California, Los Angeles in 1994. He is currently Assistant Professor in the Psychology Department at the University of Miami. He has published a number of articles and chapters in the areas of social support and distress among Hispanic breast cancer patients; influence of social support, coping, and mood on sexual risk behavior among HIV-positive men and women. His current research is focused on HIV and is supported by grants from the National Institute of Mental Health (NIMH). Dr. Durán has been recognized for his contributions and has received the NIMH’s Research Supplement for Underrepresented Minority Individuals in Post-doctoral Training, the Ford Foundation Doctoral and Dissertation Fellowship for Minorities, the UCLA Institute of American Cultures Dissertation Year Fellowship, and the NIMH Minority Clinical Training Grant.

Joe Frascella, Ph.D.
THIS IS JUST FILLER, FRASCELLLA HAS NOT RESPONDED TO MY MANY REQUESTS AS OF TODAY! On November 30, 2001, Glen R. Hanson, Ph.D., D.D.S., was named the Acting Director of the National Institute on Drug Abuse (NIDA) by Ruth Kirschstein, M.D., Acting Director of the National Institutes of Health (NIH). Dr. Hanson is an internationally recognized expert on psychostimulants. He is particularly known for his work on the neurotoxic properties of Ecstasy (MDMA) and amphetamines, as well as the role of brain peptides in psychiatric and neurological functions. As a researcher, he has been supported by grants from NIDA and the National Institute of Mental Health since the early 1980s and in 1998 received a Senior Scientist Award from NIDA. Dr. Hanson has served on several grant review committees for NIH and on the editorial board of the Journal of Pharmacology and Experimental Therapeutics. He is a frequent reviewer for most of the major pharmacology and neuroscience journals. Dr. Hanson joined NIDA in September 2000 as the director of NIDA’s Division of Neuroscience and Behavioral Research. He is a professor in the University of Utah’s Department of Pharmacology and Toxicology and holds a D.D.S. from the University of California, Los Angeles, and a Ph.D. from the University of Utah. From 1978 to 1980, Dr. Hanson was a Fellow in the National Institutes of Health Pharmacology Research Associates Training Program.

Glen Hanson, Ph.D., D.D.S.
On November 30, 2001, Glen R. Hanson, Ph.D., D.D.S., was named the Acting Director of the National Institute on Drug Abuse (NIDA) by Ruth Kirschstein, M.D., Acting Director of the National Institutes of Health (NIH). Dr. Hanson is an internationally recognized expert on psychostimulants. He is particularly known for his work on the neurotoxic properties of Ecstasy (MDMA) and amphetamines, as well as the role of brain peptides in psychiatric and neurological functions. As a researcher, he has been supported by grants from NIDA and the National Institute of Mental Health since the early 1980s and in 1998 received a Senior Scientist Award from NIDA. Dr. Hanson has served on several grant review committees for NIH and on the editorial board of the Journal of Pharmacology and Experimental Therapeutics. He is a frequent reviewer for most of the major pharmacology and neuroscience journals. Dr. Hanson joined NIDA in September 2000 as the director of NIDA’s Division of Neuroscience and Behavioral Research. He is a professor in the University of Utah’s Department of Pharmacology and Toxicology and holds a D.D.S. from the University of California, Los Angeles, and a Ph.D. from the University of Utah. From 1978 to 1980, Dr. Hanson was a Fellow in the National Institutes of Health Pharmacology Research Associates Training Program.
Steven R. López, Ph.D.
Steven R. López received his doctorate in clinical psychology from the University of California, Los Angeles in 1983. He is currently professor of psychology and psychiatry at the University of California, Los Angeles. He has published over 40 articles and chapters in the areas of the influence of sociocultural factors on psychopathology, assessment, and intervention of Latinos and other ethnic minority groups. His current research focuses on the identification of behaviors that underlie Mexican American family warmth in an effort to prevent relapse. This research is funded by a grant from the National Institute of Mental Health. Dr. López has been recognized for his contributions and has received the Distinguished Teaching Award from the Department of Psychology at UCLA. He also was one of the five science editors for the Surgeon General’s Supplemental Report on Mental Health: Culture, Race and Ethnicity.

Isaac Montoya, Ph.D.
Isaac D. Montoya received his Ph.D. from New Mexico State University in 1993. He is currently a Professor in the College of Pharmacy at the University of Houston. He has published over 75 journal articles and chapters in the areas of drug abuse research, health services research and AIDS risk behaviors. His current research is focused on drug prevention/treatment for Hispanic cocaine users, AIDS risk behaviors, and employment resulting from welfare reform. This research is supported by grants from the National Institute on Drug Abuse. Dr. Montoya has been recognized for his scientific contributions and has been listed in the Harvard Business School Press; has been a national nominating committee member for the outstanding young Americans program, and an Omicron Sigma Award recipient. In addition, he is a member of the National Institutes of Health Council (COPR).

Ivan Montoya, M.D., M.P.H.
Dr. Montoya is from Medellin, Colombia, and received his M.D. degree from the University of Antioquia (Colombia) and M.P.H. from The Johns Hopkins School of Public Health. He did residency training in Psychiatry at the San Vicente de Paul Hospital (Colombia) and University of Maryland Hospital. He was a Hubert H. Humphrey Fellow in Drug Abuse in The Johns Hopkins School of Public Health and a Visiting Fellow at the Intramural Research Program of the National Institute on Drug Abuse (NIDA). He has been Director of the Public Mental Health Program at the University of Antioquia, Consultant for the World Health Organization/Pan American Health Organization, and Director of the Practice Research Network of the American Psychiatric Association. He has published extensively in the field of prevention and treatment (pharmacological and non-pharmacological) of Substance Use Disorders. Currently, he works in the Division of Treatment Research and Development of NIDA.
Patricia Molina, M.D., Ph.D.
Patricia Molina completed medical school in 1984 at the Universidad Francisco Marroquín and a rotational internship at the Hospital General San Juan de Dios in Guatemala. In 1990, she obtained a Ph.D. in Physiology at Louisiana State University in New Orleans. She is currently Associate Professor at the Department of Physiology at Louisiana State University. She has published over 60 journal articles and chapters in the areas of alcohol consumption, the role of the nervous system in response to stress, and the role of the neuroendocrine system in modulation of pro-inflammatory responses to hemorrhagic shock. Her research is focused on neural control of hemorrhage-induced tissue cytokine production; the mechanisms involved in the accelerated muscle wasting associated with AIDS, and how chronic alcohol consumption affects the course and progression of AIDS-associated wasting. This research is funded by the Office of Naval Research, the Louisiana State University Health Sciences Center Alcohol Research Center, and the Louisiana Health Excellence Fund. Dr. Molina has been recognized for her contributions and received the Outstanding Graduate Student from Louisiana State University Medical Center in 1989.

Moira O’Brien, Ph.D.
THIS IS FILLER, NO RESPONSE YET Dr. O’Brien is Program Director, Research on Emerging and Current Trends (REACT). She has 15 years of experience in the substance abuse field and has worked within NIDA in the International Program, Office of the Director, prior to joining the Epidemiology Research Branch. Dr. O’Brien has been responsible for developing and collaborating on a number of international activities in the area of epidemiology pertaining to training, research development, and the promotion of methods and mechanisms for the collection and sharing of internationally comparable and culturally appropriate drug abuse data. Her current responsibilities include stimulating and overseeing an extramural grant program of research on emerging and current drug abuse trends, including studies to characterize the nature and extent of emerging and current drug abuse trends within local, national, and international contexts, and identify associated health, social, and behavioral consequences; enhance the identification and monitoring of emerging trends; elucidate individual, social, cultural and contextual factors influencing the initiation of emerging/current drug using behaviors; identify community- or context specific prevention and health services needs; and provide a scientific foundation for the development of appropriate interventions in response to emerging/current drug abuse trends

Angela Pattatucci, Ph.D.
Dr. Angela Pattatucci Aragón is the incoming Director of the Center for Evaluation and Sociomedical Research in the Graduate School of Public Health at the University of Puerto Rico Medical Sciences Campus. Prior to joining the faculty at UPR she spent 3 years at the NIH Center for Scientific Review, where she directed the scientific review of HIV/AIDS applications submitted for funding consideration with a focus on areas of behavioral science, prevention and epidemiology, and clinical sciences. Her doctoral research was completed at Indiana University and focused on behavior genetics and human sexuality. Her postdoctoral training was at NIH in epidemiology and adolescent mental health, spending 2 years with NICHD and an additional 2 years with NCI and the Clinical Center. She then spent 2 years as professor of epidemiology and behavioral science at the Ponce School of Medicine in Puerto Rico, followed by a year at the University of Puerto Rico as director of evaluation and assessment for the Puerto Rico Statewide Systemic Initiative (SSI), University of Puerto Rico-Río Piedras. The SSI program, aimed at all public school students in Puerto Rico, is an intervention designed to increase students’ knowledge and skills in science and math. Before returning to the NIH she spent a year at the University of Louisville as visiting professor of women’s studies and psychology. Her groundbreaking work on human sexual orientation with Dean Hamer has been hailed as a major contribution that remains extensively cited and has served as a methodological standard for defining and assessing sexual minority populations.
Presenters

Rafaela Robles, Ed.D.
Rafaela R. Robles received her Ed.D. in Sociology from Columbia University in 1970. She is currently Senior Scientist and Director of the Center for Addiction Studies of the Universidad Central del Caribe, School of Medicine. She has published over 40 journal articles and chapters in the areas of drug abuse, mental health and health care services. Her current research is focused on drug abuse and HIV prevention, transferring drug abuse research to practice, mentoring minority researchers, and a comparative study on HIV prevention. This research is supported by grants from the National Institute on Drug Abuse and the Center for Substance Abuse Treatment, among others. Dr. Robles has been recognized for her contributions and has received honors and awards from the Universidad Central del Caribe, School of Medicine (Professoris Eminentis, 1998) and the National Hispanic Science Network on Drug Abuse (Outstanding Mentorship Award, 2001).

Daniel Santisteban, Ph.D.
Daniel Santisteban earned his Ph.D. in Clinical Psychology from the University of Miami in 1991 and completed his internship at Bellevue Hospital/NYU. He is currently Research Associate Professor of Psychiatry and Behavioral Sciences at the University of Miami, Center for Family Studies. He has published over 15 articles and chapters. His interests are in treatment development, family therapy research with adolescents, and Hispanic families. Dr. Santisteban is the Principal Investigator of two grants funded by the National Institute on Drug Abuse and one funded by the American Foundation for Suicide Prevention. Dr. Santisteban has been a co-leader of the Center for Family Studies Externship program for the training of family therapists; has focused on developing new culturally appropriate family treatment interventions for specialized populations; and is leading efforts in blending research and practice at the national and state levels.

José Szapocznik, Ph.D., NHSN Chair
Dr. Szapocznik received his Ph.D. in Clinical Psychology from the University of Miami in 1977. He is currently Professor of Psychiatry and Behavioral Sciences, Psychology and Counseling Psychology at the University of Miami. Dr. Szapocznik is Director of the Center for Family Studies at the University of Miami School of Medicine. He is the founder and former director of the Miami World Health Organization Collaborating Center for Research and Training on Mental Health, Alcohol and Drug Dependence. He has published over 150 journal articles and chapters in the areas of Hispanic families, families and HIV, family therapy and family based prevention, and mental health and drug abuse policy. His current research is focused on drug abuse, HIV prevention in Hispanic adolescents, therapy with HIV+ African American women, and the role of the built environment in adolescent delinquency as well as in Hispanic elders' behavioral health. This research is supported by grants from the National Institute on Drug Abuse and the National Institute of Mental Health, among others. Dr. Szapocznik has been recognized for his contributions and has received the Presidential Award from the Society for Prevention Research, the Lifetime Achievement Award from the Latino Behavioral Health Institute, and the Substance Abuse Prevention Research Award from the U.S. Center for Substance Abuse Prevention, among others.
William Vega, Ph.D.

William Armando Vega received his Ph.D. in Criminology from the University of California, Berkeley in 1971. He is currently Professor of Psychiatry at the Robert Wood Johnson Medical School-UMDNJ. He has published over 110 journal articles and chapters in the areas of Latino mental health services research, profiles of crime, violence, and drug use among Mexican immigrants, intimate partner violence and health. His current research is focused on a culture-based model for youth violence and drug use risk-reduction funded by grants from National Institute of Child Health and Development and the National Institute of Drug Abuse, and on the health services treatment outcomes of Latino, African American, and European American heroin addicts. Additionally, Dr. Vega is co-principal investigator of the National Latino-Asian Epidemiologic Survey supported by a grant from the National Institute of Mental Health. Dr Vega has been recognized for his contributions and has received the Ralph R. Sachs Visiting Scholar in Public Health recognition award from the University of California, Los Angeles.

Keith Trujillo, Ph.D.

Keith Trujillo received his Ph.D. in Pharmacology and Toxicology from the University of California, Irvine in 1985. He is currently professor in the Department of Psychology at California State University, San Marcos. He has published over 30 journal articles and scientific book chapters in the areas of psychopharmacology and behavioral neuroscience. His current research is focused on the role of NMDA receptors in the acute and chronic behavioral actions of opiates. Dr. Trujillo’s research is supported by a grant from the National Institute of General Medical Sciences. Dr. Trujillo has been recognized for his contributions and has been named among the 2000 outstanding scientists of the 21st century. Dr. Trujillo has received the Young Investigator Award from the National Alliance for Research on Schizophrenia and Depression and the President’s Award for Scholarly and Creative Activity from California State University, San Marcos.

Frank Vocci, Ph.D.

Frank Vocci received his B.S. in biological sciences in 1971 from Loyola College. His graduate studies were concentrated in pharmacology and neuroscience at the University of Maryland at Baltimore. During that time he worked in the Clinical Neurophysiology Laboratory in the Department of Neurology and also volunteered as a staff counselor at the Tuerk House, a residential program for alcohol and drug detoxification. He received his doctoral degree in pharmacology in 1977. His post graduate training in pharmacology (1977-1978) was received at the Medical College of Virginia with Drs. William Dewey and Louis Harris. From 1978 to 1989, Dr. Vocci was employed with the Food and Drug Administration in the Drug Abuse Staff in the Division of Neuropharmacological Drug Products. He reviewed drug applications for adequacy of characterization of pharmacology and toxicology, evidence of drug efficacy, and characterization of abuse potential and possible necessity of scheduling of drugs under the Controlled Substances Act. In addition to his duties as an FDA reviewer, Dr. Vocci was also a guest researcher in the Clinical Neurosciences Branch of the National Institute on Mental Health, and an ad hoc consultant to the National Institute on Drug Abuse and the World Health organization. Since July 1989 he has been affiliated with the Medications Development Program at the National Institute on Drug Abuse where he is currently the Director of the Division of Treatment Research and Development. In his current capacity, he is responsible for instituting research and development activities for behavioral therapies and medications targeted for the treatment of opiate and stimulant abuse and dependence. Dr. Vocci has authored or co-authored over 40 articles in the field of neuropharmacology and substance abuse. In 2001, Dr. Vocci received a Presidential Meritorious Executive Award for his leadership of the treatment research effort at NIDA.
Presenters

Nora Volkow, M.D.

Nora Volkow MD is Associate Director for Life Sciences at Brookhaven National Laboratory (BNL), Chairman of the Medical Department at BNL, Director of Nuclear Medicine at BNL and Director of the NIDA-DOE Regional Neuroimaging Center at BNL. She is also an Associate Professor at the Department of Psychiatry, SUNY Stony Brook and Associate Dean for the Medical School at SUNY-Stony Brook. She has more than 260 peer-reviewed publications, three edited books, and more than 50 book chapters and non-peer reviewed manuscripts. Her main area of interest is the investigation of the mechanisms underlying the reinforcing, addictive and toxic properties of drugs of abuse in the human brain. Dr Volkow was the first to image the brain of cocaine abusers and document profound abnormalities in perfusion in these patients. She was also the first to use imaging to investigate the involvement of the neurotransmitter dopamine in the process of drug addiction. Her studies have documented a decreased in function of the dopamine brain striatal system that is associated with disruption in the function of frontal brain regions involved with drive. These results have led to a model that views drug addiction as a disease not only of reward but also of drive circuits. Dr Volkow’s work has also focused on the investigation of the neurochemical mechanisms responsible for the intersubject variability in response to drugs of abuse and its potential link to vulnerability to drug abuse and alcoholism. She has also done a systematic comparison of the pharmacological effects of cocaine (one of the most addictive drug of abuse) and of methylphenidate (drug used to treat children with attention deficit disorder) in the human brain. These studies have shown that while these two drugs have very similar distribution and potency in the human brain their pharmacokinetics differ, which may explain the much higher abuse of cocaine than of methylphenidate. The findings from these studies underscore the relevance that the route of administration plays in enabling the reinforcing effects of these drugs to occur. In parallel she has also taken advantage of imaging technologies in particular Positron Emission Tomography (PET) to investigate the changes in the dopamine system that occur with aging and their functional significance. Her work has documented that the loss of dopamine brain function with age in healthy subjects with no evidence of neurological dysfunction is nonetheless associated with motor slowing and with changes in cognitive tasks that involve executive functions. Her work now focuses on strategies to minimize the age rated losses in dopamine brain activity as a means to improve quality of life in the elderly.
Conference Planning SubCommittee

Rafaela Robles, Ed.D., Chair
Department of Community Health
Universidad Central del Caribe

Ana Anders, LCISW, Program Officer
Special Populations Office
National Institute on Drug Abuse

Ana Mari Cauce, Ph.D.
Psychology Department
University of Washington

Mari A. DiCowden, Ph.D.
The Biscayne Institutes of Health & Living, Inc.

Alexander Kopelowicz, M.D.
Department of Psychiatry
University of California-Los Angeles

Bryan Page, Ph.D.
Department of Sociology
University of Miami

José Szapocznik, Ph.D.
Department of Psychiatry & Behavioral Sciences
University of Miami

Hortensia Amaro, Ph.D.
Bouvé College of Health Sciences
Northeastern University

Edward Castañeda, Ph.D.
Department of Psychology
Arizona State University

Antonio Cepeda-Benito, Ph.D.
Department of Psychology
Texas A & M University

Jerry Flanzer, DSW,
Alternate Program Officer
Acting Deputy Branch Chief
Services Research Branch
National Institute on Drug Abuse

Ivan Montoya, M.D., Ph.D.
National Institute on Mental Health

Daniel Santisteban, Ph.D.
Department of Psychiatry & Behavioral Sciences
University of Miami
Conference Objectives

This conference is designed to identify scientific gaps and opportunities, and has also been designed to encourage interdisciplinary collaboration, the movement of basic research on etiology to prevention and treatment, and promote investigation that impacts drug abuse prevention and treatment practice.

The intent of the conference is to increase enthusiasm and interest on drug abuse research with the potential to reduce health disparities affecting Hispanic populations.

Upon completion of the conference participants will be conversant with:
1. The scientific opportunities and gaps in Hispanic drug abuse research.
2. The breadth of research conducted by Hispanic researchers - from neurobiology to anthropology.
3. The science of blending research and practice in drug abuse research.
4. The state of HIV relevant research among Hispanics.

Accreditation

This program is co-sponsored by The Biscayne Institutes of Health & Living, Inc. and the University of Miami Department of Psychiatry and Behavioral Sciences. The Biscayne Institutes of Health and Living, Inc. is approved by the American Psychological Association to offer continuing education to psychologists. The Biscayne Institutes of Health & Living, Inc. maintains responsibility for the program.

Course Hours

The Biscayne Institute of Health & Living, Inc. designates this educational activity for 14 credit hours toward continuing education for Psychologists.
National Hispanic Science Network on Drug Abuse

National Office
Center for Family Studies
University of Miami
1425 NW 10th Avenue, 3rd Floor
Miami, FL 33136
305.243.2340 phone
305.243.5577 fax
www.hispanicscience.org

National Office Staff
Yolanda Mancilla, Ph.D., National Coordinator
Veronica Maldonado, Program Assistant
Grettel Fernandez, Research Assistant
Zuny Fernandez, Conference Support Staff
Jacqueline Lopez, Conference Support Staff
Lissette Mendez, Conference Support Staff

Northeastern University Staff
Amanda Navarro, M.P.H.

National Institute on Drug Abuse
Ana Anders, LCISW, Program Officer
Special Populations Office

Jerry Flanzer, DSW, Alternate Program Officer
Acting Deputy Branch Chief, Services Research Branch

Very Special Thanks to:
Ana Anders, LCISW, Program Officer, Special Populations Office
Manuel Diaz, Precise Printing, Inc.
Diana Soto, FourSeasons Travel
Special Thanks to Our Co-Sponsor: